Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MOSAIC, a Phase 2a trial evaluating ECC4703, ECC0509 and their combination in adults with presumed metabolic dysfunction-associated steatohepatitis (MASH).Read More
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been dosed in a Phase 1b clinical trial of AZD5004/ECC5004 in China. The earlier Phase 1 trial of AZD5004/ECC5004 was conducted in the U.S. only and this trial in China isRead More
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that preclinical data from a combination study of its wholly owned, highly selective liver-targeting THR-ß full agonist, ECC4703, together with a GLP-1 receptor agonist were selected for a late-breaking poster presentation at the American Diabetes Association’sRead More
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced the formation of its Scientific Advisory Board (SAB), comprised of four renowned cardiometabolic disease experts. The SAB will serve as a strategic resource to Eccogene as it continues to advance its pipeline of novel oral smallRead More
Boston, Mass. and Shanghai—November 15, 2024— Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that two late-breaking abstracts on new Phase 1 data covering its novel oral THR-β full agonist (ECC4703) and oral SSAO inhibitor (ECC0509) will be reviewed in poster presentations at theRead More
Boston, Mass. and Shanghai—October 23, 2024— Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in theRead More
Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene’s small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. GLP-1RA represents a very important class of drugs for multiple cardiometabolic diseases; currently there is noRead More
Eccogene, Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY 180 million (about $25 million) Series B financing. The financing was co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital. The syndicate also included new investors Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture and existing investorsRead More
Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mellitus (T2DM). This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC5004 in healthy participantsRead More
Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants and subjects with elevated LDL. Thyroid hormone receptorRead More